124 related articles for article (PubMed ID: 8282116)
1. A new application for liposomes in cancer therapy. Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of prodrugs.
Vingerhoeds MH; Haisma HJ; van Muijen M; van de Rijt RB; Crommelin DJ; Storm G
FEBS Lett; 1993 Dec; 336(3):485-90. PubMed ID: 8282116
[TBL] [Abstract][Full Text] [Related]
2. Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity.
Vingerhoeds MH; Haisma HJ; Belliot SO; Smit RH; Crommelin DJ; Storm G
Pharm Res; 1996 Apr; 13(4):604-10. PubMed ID: 8710754
[TBL] [Abstract][Full Text] [Related]
3. A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.
Haisma HJ; Boven E; van Muijen M; de Jong J; van der Vijgh WJ; Pinedo HM
Br J Cancer; 1992 Sep; 66(3):474-8. PubMed ID: 1520585
[TBL] [Abstract][Full Text] [Related]
4. Design of immuno-enzymosomes with maximum enzyme targeting capability: effect of the enzyme density on the enzyme targeting capability and cell binding properties.
Fonseca MJ; Haisma HJ; Klaassen S; Vingerhoeds MH; Storm G
Biochim Biophys Acta; 1999 Jul; 1419(2):272-82. PubMed ID: 10407077
[TBL] [Abstract][Full Text] [Related]
5. Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate.
Fonseca MJ; Jagtenberg JC; Haisma HJ; Storm G
Pharm Res; 2003 Mar; 20(3):423-8. PubMed ID: 12669963
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-beta-glucuronidase conjugate in the specific treatment of cancer.
Haisma HJ; van Muijen M; Pinedo HM; Boven E
Cell Biophys; 1994; 24-25():185-92. PubMed ID: 7736523
[TBL] [Abstract][Full Text] [Related]
7. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
[TBL] [Abstract][Full Text] [Related]
8. Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy.
Fonseca MJ; Storm G; Hennink WE; Gerritsen WR; Haisma HJ
J Gene Med; 1999; 1(6):407-14. PubMed ID: 10753066
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells.
Koning GA; Gorter A; Scherphof GL; Kamps JA
Br J Cancer; 1999 Aug; 80(11):1718-25. PubMed ID: 10468287
[TBL] [Abstract][Full Text] [Related]
10. Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy.
Houba PH; Leenders RG; Boven E; Scheeren JW; Pinedo HM; Haisma HJ
Biochem Pharmacol; 1996 Aug; 52(3):455-63. PubMed ID: 8687500
[TBL] [Abstract][Full Text] [Related]
11. In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice.
Nässander UK; Steerenberg PA; Poppe H; Storm G; Poels LG; De Jong WH; Crommelin DJ
Cancer Res; 1992 Feb; 52(3):646-53. PubMed ID: 1732053
[TBL] [Abstract][Full Text] [Related]
12. Characterization of an antineoplastic glucuronide prodrug.
Cheng TL; Chou WC; Chen BM; Chern JW; Roffler SR
Biochem Pharmacol; 1999 Jul; 58(2):325-8. PubMed ID: 10423174
[TBL] [Abstract][Full Text] [Related]
13. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy.
Wang SM; Chern JW; Yeh MY; Ng JC; Tung E; Roffler SR
Cancer Res; 1992 Aug; 52(16):4484-91. PubMed ID: 1643640
[TBL] [Abstract][Full Text] [Related]
14. Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells.
Koning GA; Morselt HW; Velinova MJ; Donga J; Gorter A; Allen TM; Zalipsky S; Kamps JA; Scherphof GL
Biochim Biophys Acta; 1999 Aug; 1420(1-2):153-67. PubMed ID: 10446299
[TBL] [Abstract][Full Text] [Related]
15. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue.
Chen KC; Schmuck K; Tietze LF; Roffler SR
Mol Pharm; 2013 May; 10(5):1773-82. PubMed ID: 23448264
[TBL] [Abstract][Full Text] [Related]
16. Cell surface display of a lysosomal enzyme for extracellular gene-directed enzyme prodrug therapy.
Heine D; Müller R; Brüsselbach S
Gene Ther; 2001 Jul; 8(13):1005-10. PubMed ID: 11438835
[TBL] [Abstract][Full Text] [Related]
17. Expression of active human beta-glucuronidase in Sf9 cells infected with recombinant baculovirus.
Sperker B; Mürdter TE; Backman JT; Fritz P; Kroemer HK
Life Sci; 2002 Aug; 71(13):1547-57. PubMed ID: 12127909
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of dexamethasone-beta-D-glucuronide for colon-specific drug delivery.
Haeberlin B; Rubas W; Nolen HW; Friend DR
Pharm Res; 1993 Nov; 10(11):1553-62. PubMed ID: 8290467
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT).
Leu YL; Roffler SR; Chern JW
J Med Chem; 1999 Sep; 42(18):3623-8. PubMed ID: 10479293
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard.
Lougerstay-Madec R; Florent JC; Monneret C; Nemati F; Poupon MF
Anticancer Drug Des; 1998 Dec; 13(8):995-1007. PubMed ID: 10335272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
